Influenza Vaccination in Patients With Scleroderma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01002508|
Recruitment Status : Unknown
Verified August 2009 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : October 27, 2009
Last Update Posted : October 27, 2009
|Condition or disease||Intervention/treatment||Phase|
|Influenza Vaccine in Scleroderma||Biological: Influenza vaccine||Phase 4|
Fifty patients with scleroderma and 30 healthy , aged matched controls will participate in the study.
After signing informed consent, all subjects will be vaccinated with the inactivated split virion vaccine which recommended by the WHO this fall.
Patients will be evaluated at weel 0 and 6 weeks later. Clinical evaluation will be based on the modified Rodnan score, number of digital ischemic ulcers, presence of gastrointestinal and respiratory symptoms, number of swollen and tender joints, visual global evaluation of the physician , ESR and CRP Blood with be collected on the day of vaccination and 6 weeks later.
The immunogenicity of the vaccine will be tested by Haemagglutination inhibition (HI) test.
Influenza virus has two important surface glycoproteins: the haemagglutinin (HA) and the neuraminidase (NA). Antigenic classification and subtyping of influenza viruses is based on these two glycoproteins. HA plays a key role in virus cell entry by binding to cell surface receptors, which are found also on red blood cells of certain species. Binding to red cells results in haemagglutination, which can be observed as a carpet of agglutinated red cells at the bottom of a tube or microtitre well. In the HI test, antibody directed against the viral haemagglutinins block the virus from binding to the blood cells and thus inhibits the haemagglutination reaction.
The pre- and post immunization HI antibodies were tested at the Central Virology Laboratory of the Israeli Ministry of Health using the HI test according to a standard WHO procedure 16. Sera were separated, code labeled, and stored at -20°C until tested. Sera were treated with receptor destroying enzyme cholera filtrate to remove non-specific inhibitors, and with Turkey red blood cells to remove non-specific agglutinins. The treated sera were tested by HI test against the three antigens included in the vaccine: A/California (CAL), A/Wisconsin and B/Malaysia. The working dilution (test dose) of each antigen contained four haemagglutinin units in 25 µl of antigen. Test doses were diluted in phosphate buffered saline (PBS) and added to serial dilution of antiserum. The haemagglutinin inhibition titer was determined as the highest dilution of serum that completely inhibits haemagglutination of red blood cells.
The titer of an antiserum not showing any inhibition will be recorded as <10. Humoral response will be defined as either a fourfold or more rise in titer, or a rise from a non-protective baseline level of <1/40 to 1/40 in HI antibodies four weeks after vaccination 17,18. Geometric mean titers of antibody will be calculated to assess the immunity of the whole group.
Primary Endpoint of the study : the proportion of patients who achieve a titer of antibodies above 1/40, against each of the antigens included in the vaccine Secondary Endpoint: Safety of the vaccine
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma|
|Study Start Date :||November 2009|
|Estimated Primary Completion Date :||March 2010|
|Estimated Study Completion Date :||March 2010|
- Biological: Influenza vaccine
One dose of influenza vaccine
- The number of subjects who achieve a titer of antibodies above 1/40 [ Time Frame: 6 weeks ]
- Number of patients with an increased Rodnan Score [ Time Frame: 6 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01002508
|Contact: Ira Litinsky, MDemail@example.com|
|Contact: Ori Elkayam, M.Dfirstname.lastname@example.org|
|Tel Aviv Medical Center||Not yet recruiting|
|Tel AVIV, Israel, 64239|
|Contact: Ayelet Brill 972524266894 email@example.com|
|Contact: Ori Elkayam 97236973668 firstname.lastname@example.org|
|Principal Investigator: Ira Litinsky, MD|
|Sub-Investigator: Ori Elkayam, MD|